Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has successfully synthesized multiple short-acting MDMA analogs and has filed a patent covering these novel molecules. Experts at Mydecine specifically designed the family of analogs, which has been named MYCO-006, to have a shorter half-life than traditional MDMA. The patent application has been filed with the World Intellectual Property Organization. Often referred to as ecstasy, 3,4-methylenedioxymethamphetamine, or MDMA, is a synthetic drug that acts as a stimulant and hallucinogen. Mydecine has been working with the substance, having filed a provisional patent application for a family of MDMA-like compounds last year that was designed to reduce harm and improve safety compared to the traditional drug. According to the company, research that shows MDMA has the potential to make therapy of all types more effective as it has been shown to increase feelings of well-being and interpersonal trust while decreasing feelings of fear and defensiveness. However, one of the challenges of using the substance in therapy is that the effects of the drug last eight hours or longer; Mydecine believes that in order to make treatments accessible to the majority of the population, shorter-acting medicine might be more safe and effective in some situations. According to the announcement, the company is hoping to decrease the half-life of MDMA, resulting in treatments that can be easily repeated at a typical healthcare facility, making the treatments more accessible and affordable. “For these treatment modalities to be adopted and accepted by the general medical community, there must be a drug product that can be administered at existing clinics and hospitals in less time, and that will be reimbursed by insurance providers. We believe shortening the half life of MDMA is an important necessary step to making this possible,” said Mydecine Innovations CEO Josh Bartch in the press release. “Considering the incredible efficacy data being published on MDMA, and the frequent effect of boosting trust and well-being, we are incredibly excited about the potential to increase health equity for the large population in need with our MYCO-006 family of novel molecules.”
To view the full press release, visit https://ibn.fm/m64E2
About Mydecine Innovations Group
Mydecine Innovations is a biotechnology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction using world-class technology and drug-development infrastructure. Mydecine was founded in 2020 to address a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. The company’s global team is dedicated to efficiently developing new therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The Mydecine business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy as well as other novel, nonpsychedelic molecules with therapeutic potential. By collaborating with some of the world’s foremost authorities, Mydecine aims to responsibly fast-track the development of new medicines to provide patients suffering from mental health disorders with safe and more effective treatment options. Mydecine Innovations Group is headquartered in Denver, Colorado, with international offices in Leiden, Netherlands. For more information about the company, please visit www.Mydecine.com
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
